Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report

• Published in: The oncologist (Dayton, Ohio) Ohio), 2024-06, Vol.29 (6), p.543-545
• Main Authors: Wang, Huaiyu, Fan, Zaiwen, Yang, Xiaoming, Wu, Qing, Jiang, Suxin, Zhu, Jingna, Liu, Jie, Zhou, Chuanhong, Liu, Yinghui, You, Xia, Han, Yong
• Format: Article
• Language: English
• Subjects: Aged; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - surgery; Care and treatment; Complications and side effects; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Female; Genetic aspects; Humans; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Male; Middle Aged; Mutation; Neoplasm Metastasis; Precision Medicine Clinic: Molecular Tumor Board; Protein Kinase Inhibitors - therapeutic use; Tyrosine Kinase Inhibitors
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1093/oncolo/oyad339

Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.